New report from GoodRx tracks changes in GLP-1 insurance coverage
In 2025, the number of people without commercial insurance coverage for these medications surged significantly. Zepbound saw a 14% increase since 2024, leaving 4.9 million people without coverage, and Ozempic saw a 22% increase, affecting another 1.1 million people.
